Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Bimagrumab

Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

Eli Lilly · Phase 2 · Completed · Enrollment 507

NCT05616013

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

X axis: threshold category. Y axis: participants reaching threshold, %.

4058.197.773.392.297.6100
≥5%
≥10%
≥15%
≥20%
  • Placebo/30 mg/kg Bimagrumab
  • 10/30 mg/kg Bimagrumab
  • 30 mg/kg Bimagrumab
  • Placebo + 1.0 mg Semaglutide
  • Placebo + 2.4 mg Semaglutide
  • 10 mg/kg Bimagrumab + 1.0 mg Semaglutide
  • 10 mg/kg Bimagrumab + 2.4 mg Semaglutide
Show as table
Arm≥5%≥10%≥15%≥20%
Placebo/30 mg/kg Bimagrumab40%n/rn/rn/r
10/30 mg/kg Bimagrumab58.1%n/rn/rn/r
30 mg/kg Bimagrumab97.7%n/rn/rn/r
Placebo + 1.0 mg Semaglutide73.3%n/rn/rn/r
Placebo + 2.4 mg Semaglutide92.2%n/rn/rn/r
10 mg/kg Bimagrumab + 1.0 mg Semaglutide97.6%n/rn/rn/r
10 mg/kg Bimagrumab + 2.4 mg Semaglutide100%n/rn/rn/r
30 mg/kg Bimagrumab + 1.0 mg Semaglutiden/rn/rn/rn/r
30 mg/kg Bimagrumab + 2.4 mg Semaglutiden/rn/rn/rn/r

Not shown

  • 30 mg/kg Bimagrumab + 1.0 mg Semaglutide: endpoint not reported
  • 30 mg/kg Bimagrumab + 2.4 mg Semaglutide: endpoint not reported